Dermata Therapeutics, Inc. DRMA
Set alert
At close · Oct 30
After hours · Oct 30, 7:59 PM ET
- YTD
- -66.59%
- 1 year
- -77.41%
- Open
- 0.799
- Prev close
- 0.8302
- Mkt cap
- 3.84M
- Vol
- 62.20K
- Avg vol
- 3.44M
- EPS
- -4.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7637
- High
- 0.829
- Forward P/E
- -0.32
- Beta
- 0.79
- Short ratio
- 0.52
- Inst. own
- 0.66%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.27
- 200-d avg
- 2.84
- 1y target
- 6.00
3M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
Key statistics
- Market cap
- 2.51M
- Enterprise value
- -3.38M
- Trailing P/E
- 0.00
- Forward P/E
- -0.32
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.05
- EPS (TTM)
- -13.36
- Beta
- 0.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.24M
- Total cash
- 4.95M
- Total debt
- 0
- Return on equity
- -173.01%
- Shares outstanding
- 2.04M
- Short % of float
- 6.28%
- 50-day average
- 1.27
- 200-day average
- 2.84
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -2.04 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -4.18 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -7.05 | — | — |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -3.15 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -8.10 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -9.45 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 2024 | Maxim Group | main | Buy | Buy |
| Mar 23, 2023 | Maxim Group | main | — | Buy |
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dermatarx.com
News
- Dermata Therapeutics Enrolls First Participant In Its Clinical Trial Evaluating Tome Clearing Treatment For Acne; Expects To Launch This Second Commercial Product In H1 2027
- Why Is Dermata Therapeutics Stock Gaining Thursday?
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
- Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
- Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
- Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on DRMA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.14% | 2,892 | 3.56K | Sep 29, 2024 |
| Wells Fargo & Company | 0.10% | 2,045 | 2.52K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 1,497 | 1.84K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 10 | 12 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.32% | 6,582 | 8.10K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 1,826 | 2.25K | Oct 30, 2024 |